Using the Composite Immune Risk Score to Assess and Modulate the Patient's Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation, a Prospective, Multicenter, Randomized Controlled Study.

What this Trial Is About

Researchers are evaluating how well the Composite Immune Risk Score (CIRS) works for patients who have received allogeneic hematopoietic stem cell transplantation. The study aims to see if this score can effectively assess and guide immune system recovery after transplant in a real-world clinical setting. The research is a prospective, multicenter, randomized controlled study focusing on patients with transplant-related disorders. Participants are divided into two groups. One group receives health monitoring along with regular reminders to return for blood tests and follow-up visits up to one year after transplant. Physicians use the CIRS to assess the immune risk level of patients between 91 and 180 days post-transplant. The other group only receives reminders to test their immune status between 120 and 180 days after transplantation. During the study, participants will be monitored for survival and immune recovery for 1.5 years after transplantation. Researchers will collect data on survival rates, non-relapse mortality, infections, and immune cell counts. The study involves regular follow-up visits and blood tests to track immune status and overall health. Participants must be at least 16 years old and have undergone haploidentical allo-HSCT to join the study.

Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.